5d 1m 3m 1y 5y 10y
There are no Transcripts on FATE.
Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic MalignanciesGlobeNewswire (Wed, 7:01AM)
GlobeNewswire (Feb 28, 2014)
GlobeNewswire (Feb 27, 2014)
FATE vs. ETF Alternatives
Monday, Oct 282013, 8:55 AM
Wednesday, Oct 92013, 12:46 PM|Wednesday, Oct 92013, 12:46 PM| Comment!
Tuesday, Oct 12013, 11:23 AM
Tuesday, Oct 12013, 11:23 AM| Comment!
- Fate Therapeutics (FATE +13%) opens at $6.56 and moves sharply higher.
- The offering priced at the low-end of its expected range, notable because the company had already lowered the range to $6-8 from $14-16.
- FATE's lead product is ProHema, a hematopoietic stem cell therapeutic derived from umbilical cord blood.